The first gene therapies approved to treat sickle cell disease in December 2023 are struggling on the market. But there are glimpses of forward momentum as Vertex and Genetix Bio provide updates.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor ...

Gene editing, a set of techniques used to alter sections of an organism's DNA, is helping scientists cure diseases previously ...

Serenity Cole enjoyed Christmas last month relaxing with her family near her St. Louis home, making crafts and visiting friends. It was a contrast to how Cole, 18, spent part of the 2024 holiday ...

Vertex Pharmaceuticals and Orum Therapeutics are striking a deal to make new conditioning drugs for patients going on the Boston biotech's gene editing treatment, Casgevy. This story was originally ...

Add Yahoo as a preferred source to see more of our stories on Google. A sign hangs in front of the world headquarters of Vertex Pharmaceuticals in Boston, Massachusetts, U.S., October 23, 2019.

Vertex Pharmaceuticals (NASDAQ:VRTX) management emphasized revenue growth, expanding product diversification, and multiple ...

A lot can change in five years. Take Vertex Pharmaceuticals (NASDAQ: VRTX), for example. In late 2020, the big biotech company's approved products focused on one indication – cystic fibrosis (CF). And ...

Given the company's vast healthcare ecosystem, deep footprint across the U.S., and relationships with customers, CVS' ongoing ...

(RTTNews) - WuXi Biologics (2269. HK,WXIBF), a Contract Research, Development, and Manufacturing Organisation, announced on Tuesday that it has signed a license and research service agreement with ...